What is PBD Biotech?
PBD Biotech operates at the intersection of biotechnology and agricultural science, specializing in the development of novel phage-based diagnostic tools. The company's core competency lies in its proprietary technology designed to detect mycobacteria, specifically Mycobacterium Bovis and Mycobacterium avium subsp. paratuberculosis. These pathogens are primary drivers of bovine TB and Johne's disease, respectively, both of which represent substantial threats to global agricultural productivity and animal welfare.
By providing highly accurate and rapid diagnostic solutions, PBD Biotech enables producers to manage herd health with unprecedented precision. The company's market position is defined by its ability to translate complex biological research into actionable field-ready diagnostics, effectively bridging the gap between laboratory innovation and practical veterinary application.
How much funding has PBD Biotech raised?
PBD Biotech has raised a total of $3.2M across 1 funding round:
Unspecified
$3.2M
Unspecified (2021): $3.2M with participation from Mercia Group and Foresight Group
Key Investors in PBD Biotech
Mercia Group
Mercia Group is a prominent investment firm that provides comprehensive support and capital to high-growth businesses, focusing on scaling innovative technologies across various sectors.
Foresight Group
Foresight Group is a leading independent infrastructure and private equity investment manager with a long-standing history of supporting sustainable and impactful business ventures.
What's next for PBD Biotech?
Looking ahead, the strategic deployment of the $3.2M will likely focus on expanding the commercial reach of PBD Biotech's diagnostic suite. As the company transitions into a more mature phase of enterprise-level operations, the focus will shift toward scaling manufacturing processes and broadening the regulatory approval footprint for its phage-based assays. The backing from established investment firms suggests a long-term strategy aimed at standardizing these diagnostic protocols within international agricultural markets.
Furthermore, the company is expected to prioritize research and development initiatives that could potentially extend its diagnostic platform to other infectious diseases. By maintaining a rigorous focus on technical excellence and market penetration, PBD Biotech is poised to become a cornerstone provider of health security solutions for the global livestock sector.
